<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546648</url>
  </required_header>
  <id_info>
    <org_study_id>POISE3034</org_study_id>
    <nct_id>NCT02546648</nct_id>
  </id_info>
  <brief_title>PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study</brief_title>
  <acronym>POISE-3</acronym>
  <official_title>PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study (POISE-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A placebo-controlled, factorial trial to assess the impact of rosuvastatin and tranexamic
      acid (TXA) in patients undergoing noncardiac surgery who are at risk of a perioperative
      cardiovascular event.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The POISE-3 pilot is a randomized controlled trial of 100 patients with, or at risk of,
      atherosclerotic disease who are undergoing noncardiac surgery. Utilizing a partial factorial
      design, the POISE-3 pilot will determine the effect of rosuvastatin versus placebo and TXA
      versus placebo in the perioperative setting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative intervention discontinuation</measure>
    <time_frame>Postoperative day 1 to 30.</time_frame>
    <description>Interruption of the intervention longer than 24 hours within the first 10 days postoperatively, and longer than 48 hours from postoperative day 10 to 30.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>Postoperative day 1.</time_frame>
    <description>Change in preoperative hemoglobin to the morning hemoglobin recorded on day 1 after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Postoperative day 30.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal myocardial infarction</measure>
    <time_frame>Postoperative day 30.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A composite of vascular mortality and non-fatal: myocardial infarction, stroke, cardiac arrest, pulmonary embolus, deep venous thrombosis, life threatening bleeding, major bleeding.</measure>
    <time_frame>Postoperative day 30.</time_frame>
    <description>Event composite</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Outcomes for Rosuvastatin assessed by Statin induced myopathy</measure>
    <time_frame>Postoperative day 30.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes for Tranexamic Acid assessed by Seizure, pulmonary emboli, deep venous thrombosis, vascular mortality</measure>
    <time_frame>Postoperative day 30.</time_frame>
    <description>myocardial infarction, stroke, non-fatal cardiac arrest, and cardiac revascularization procedure.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Atherosclerotic Disease</condition>
  <condition>Perioperative Bleeding</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid vs. matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic Acid 1g bolus with anesthesia induction followed by 1g bolus at the start of surgical closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin vs. matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20 mg orally or matching placebo once per day until 30 days after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Tranexamic Acid vs. matching placebo</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Placebo</intervention_name>
    <arm_group_label>Tranexamic Acid vs. matching placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin or matching placebo</intervention_name>
    <description>Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.</description>
    <arm_group_label>Rosuvastatin vs. matching placebo</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. undergoing noncardiac surgery

          2. &gt;45 years of age

          3. expected to require at least an overnight hospital admission after surgery; AND

          4. have a preoperative NT-pro-BNP measurement &gt;100 ng/mL; OR

          5. if a preoperative NT-pro-BNP measurement is not available, then the patient must
             fulfill 1 or more of the following 5 criteria:

               -  history of coronary artery disease

               -  history of peripheral vascular disease

               -  history of stroke

               -  undergoing major vascular surgery

               -  have any 3 of the following 9 risk criteria:

                    -  undergoing major surgery

                    -  history of congestive heart failure

                    -  history of a transient ischemic attack

                    -  diabetic and currently taking an oral hypoglycemic agent or insulin

                    -  age &gt;70 years

                    -  hypertension

                    -  serum creatinine &gt; 175 umol/L (&gt;2.0 mg/dl)

                    -  history of smoking within 2 years of surgery

                    -  undergoing emergent/urgent surgery

        Exclusion Criteria:

          1. planned use of systemic Tranexamic Acid during surgery

          2. hypersensitivity or known allergy to TXA

          3. creatinine clearance &lt;30 mL/min (MDRD)

          4. history of seizure disorder

          5. history of venous thromboembolism

          6. acute arterial thrombosis

          7. no preoperative measurement of hemoglobin

          8. subarachnoid hemorrhage within the past 30 days

          9. hematuria caused by diseases of the renal parenchyma

         10. previously enrolled in POISE-3 pilot trial

         11. not consenting to participate in POISE-3 pilot trial prior to surgery

        Patients meeting any of the following criteria will be excluded from the
        Rosuvastatin/Placebo arm:

          1. preoperative treatment with a statin or a non statin lipid lowering drug or
             ciclosporin during the 48 hours before surgery

          2. hypersensitivity or known allergy to Rosuvastatin

          3. pre-disposed factors for myopathy or rhabdomyolysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Khan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

